Furukawa, T.; Okada, K.; Abe, M.; Tei, R.; Oikawa, O.; Maruyama, N.; Maruyama, T.
Randomized Controlled Trial of Darbepoetin α Versus Continuous Erythropoietin Receptor Activator Injected Subcutaneously Once Every Four Weeks in Patients with Chronic Kidney Disease at the Pre-Dialysis Stage. Int. J. Mol. Sci. 2015, 16, 30181-30189.
https://doi.org/10.3390/ijms161226229
AMA Style
Furukawa T, Okada K, Abe M, Tei R, Oikawa O, Maruyama N, Maruyama T.
Randomized Controlled Trial of Darbepoetin α Versus Continuous Erythropoietin Receptor Activator Injected Subcutaneously Once Every Four Weeks in Patients with Chronic Kidney Disease at the Pre-Dialysis Stage. International Journal of Molecular Sciences. 2015; 16(12):30181-30189.
https://doi.org/10.3390/ijms161226229
Chicago/Turabian Style
Furukawa, Tetsuya, Kazuyoshi Okada, Masanori Abe, Ritsukou Tei, Osamu Oikawa, Noriaki Maruyama, and Takashi Maruyama.
2015. "Randomized Controlled Trial of Darbepoetin α Versus Continuous Erythropoietin Receptor Activator Injected Subcutaneously Once Every Four Weeks in Patients with Chronic Kidney Disease at the Pre-Dialysis Stage" International Journal of Molecular Sciences 16, no. 12: 30181-30189.
https://doi.org/10.3390/ijms161226229
APA Style
Furukawa, T., Okada, K., Abe, M., Tei, R., Oikawa, O., Maruyama, N., & Maruyama, T.
(2015). Randomized Controlled Trial of Darbepoetin α Versus Continuous Erythropoietin Receptor Activator Injected Subcutaneously Once Every Four Weeks in Patients with Chronic Kidney Disease at the Pre-Dialysis Stage. International Journal of Molecular Sciences, 16(12), 30181-30189.
https://doi.org/10.3390/ijms161226229
